Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Abuse Potential of PF614 in Recreational Opioid Users
NCT05571345Phase 1Completed
- Sponsor
- Ensysce Biosciences
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF614 in pain (5 arms), sponsored by Ensysce Biosciences. Primary endpoints: Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale (VAS) at 24 hours and Take Drug Again VAS (Emax) at 24 hours. Started Oct 2022; status: completed.
02
Drugs
PF614
03
Conditions
pain
Beyond the preview
Go deeper on NCT05571345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571345.